How Gene Changes Affect SSADH Deficiency Symptoms

What was studied

Researchers looked at a rare inherited neurometabolic disorder called succinic semialdehyde dehydrogenase deficiency (SSADHD), which is caused by variants in the ALDH5A1 gene. They collected clinical and molecular information from 12 probands, who had symptoms including epilepsy, intellectual disorders, developmental delay, and hypotonia.

They then studied 14 ALDH5A1 variants to assess how each one affected the SSADH protein. The team used multiple in silico prediction tools, quantitative tests of protein expression and residual enzyme activity, and 3D structural modeling to evaluate whether these variants were likely disease-causing under ACMG/AMP genetic classification guidelines.

What they found

The study found that the 14 ALDH5A1 variants affected SSADH structure and function in different ways and to different degrees. Nine variants affected SSADH protein expression, and nine affected SSADH enzyme activity. Functional results supported assignment of ACMG PS3 evidence to 10 variants and BS3 evidence to 1 variant.

The modeling and protein-based prediction analyses suggested several possible mechanisms: 2 variants influenced binding of SSADH to small molecules, 3 variants led to instability, and variants in the oligomerization domain were associated with accumulation in the tetramer and increasing tetramer instability. Overall, the authors say these results provide additional evidence for classifying these variants and may help future genetic diagnosis of SSADHD.

Limits of the evidence

This was a small study, with clinical data from 12 people and testing focused on 14 variants. It mainly examined effects on protein expression, enzyme activity, and predicted structural changes, rather than directly linking each variant to a person's exact symptoms.

Because SSADHD shows phenotypic heterogeneity, this study does not show that a specific variant will always be associated with a certain level of epilepsy, intellectual problems, developmental delay, or hypotonia. The abstract also does not provide detailed patient outcomes or larger-group comparisons.

For families and caregivers

For families, this study may matter because it helps explain how certain ALDH5A1 variants can affect the SSADH enzyme. Better variant classification may make genetic test results clearer and may reduce uncertainty about whether a specific change is related to SSADHD.

It does not report a new treatment or predict exactly how a child will do, but it may support more accurate diagnosis and genetic counseling when this rare condition is being considered.

What to watch next

Useful next steps would include larger studies that compare specific ALDH5A1 variants with clinical features over time and further evaluate these functional and structural findings in additional patients and variants.

Terms in this summary

ALDH5A1

The gene that provides instructions for making the SSADH enzyme.

SSADH

An enzyme involved in breaking down succinic semialdehyde; reduced or altered function causes SSADHD.

SSADHD

A rare inherited neurometabolic disorder caused by altered SSADH enzyme function.

variant

A change in a gene's DNA sequence.

enzyme activity

How well an enzyme carries out its function in lab testing.

ACMG/AMP guidelines

Standard criteria used by genetics experts to classify whether a gene variant is likely harmful or benign.

3D structural modeling

Methods used to predict how a protein's three-dimensional shape may be affected by a variant.

oligomerization domain

The part of a protein involved in joining with other protein units to form a larger functional complex.